Home | | Pharmacology | Cholinoceptor Blocking Drugs

Chapter: Basic & Clinical Pharmacology : Cholinoceptor Blocking Drugs

Cholinoceptor Blocking Drugs

Cholinoceptor antagonists, like agonists, are divided into muscarinic and nicotinic subgroups on the basis of their specific receptor affinities.

Cholinoceptor Blocking Drugs

Cholinoceptor antagonists, like agonists, are divided into muscarinic and nicotinic subgroups on the basis of their specific receptor affinities. Ganglion blockers and neuromuscular junction blockers make up the antinicotinic drugs.

Five subtypes of muscarinic receptors have been identified, primarily on the basis of data from ligand-binding and cDNA-cloning experiments. A standard terminol-ogy (M1 through M5) for these subtypes is now in common use, and evidence—based mostly on selective agonists and antagonists— indicates that functional differences exist between several of these subtypes.

The M1 receptor subtype is located on central nervous system (CNS) neurons, sympathetic postganglionic cell bodies, and many presynaptic sites. M 2 receptors are located in the myocar-dium, smooth muscle organs, and some neuronal sites. M3 recep-tors are most common on effector cell membranes, especially glandular and smooth muscle cells. M4 and M5 receptors are less prominent and appear to play a greater role in the CNS than in the periphery.

 CASE STUDY

JH, a 63-year-old architect, complains of urinary symptoms to his family physician. He has hypertension, and during the last 8 years, he has been adequately managed with a thiazide diuretic and an angiotensin-converting enzyme inhibitor. During the same period, JH developed the signs of benign prostatic hypertrophy, which eventually required prostatectomy to relieve symptoms. He now complains that he has an increased urge to urinate as well as urinary fre-quency, and this has disrupted the pattern of his daily life. What do you suspect is the cause of JH’s problem? What information would you gather to confirm your diagnosis? What treatment steps would you initiate?

 

CASE STUDY ANSWER

JH’s symptoms are often displayed by patients following prostatectomy to relieve significant obstruction of bladder outflow. Urge incontinence can occur in patients whose pro-static hypertrophy caused instability of the detrusor muscle. He should be advised that urinary incontinence and urinary frequency can diminish with time after prostatectomy as detrusor muscle instability subsides. JH can be helped by daily administration of a single tablet of extended-release tolterodine (4 mg/day) or oxybutynin (5–10 mg/day). A transdermal patch containing oxybutynin (3.9 mg/day) is also available.


Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Basic & Clinical Pharmacology : Cholinoceptor Blocking Drugs : Cholinoceptor Blocking Drugs |


Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.